Printer Friendly

CHRONIMED ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH HARVARD UNIVERSITY

 MINNEAPOLIS, June 17 /PRNewswire/ -- The Orphan Medical division of CHRONIMED Inc. (NASDAQ: CHMD), Minneapolis, today announced the signing of an exclusive, worldwide license agreement with Harvard University to dispense a special form and dosage of vitamin A to be marketed as Unilife-A(TM) which has not previously been commercially available. A use patent has been applied for by Harvard University for the treatment of retinitis pigmentosa (RP). The product is now available from Orphan Medical, P.O. Box 47945, Minneapolis, Minn. 55447.
 Several dosages of vitamins A and E were tested and regular daily use of this specific dosage form of vitamin A was effective in a seven- year study sponsored by the National Eye Institute. The principal investigator was Eliot L. Berson, M.D. of the Harvard Medical School. Alan M. Laties, M.D., chairman of the RP Foundation's Scientific Advisory Board said, "Although not a cure, it will improve quality of life, potentially adding many years of useful vision."
 RP is a group of inherited diseases initially manifesting as night blindness, followed by progressive loss of peripheral vision. Over a period of years, this results in "tunnel vision" and may lead to total blindness. The majority of people with RP are legally blind by the age of 40. An estimated 1.5 million people worldwide are affected by RP.
 CHRONIMED is a health care company specializing in the unique needs of patients with chronic diseases. CHRONIMED provides: patient education, pharmaceuticals, general medical and clinical nutrition products directly to the individual and to the patients of managed care and case management companies nationwide.
 -0- 6/17/93
 /CONTACT: Maurice R. Taylor, II, of CHRONIMED Inc., 612-541-0239/
 (CHMD)


CO: CHRONIMED Inc. ST: Minnesota IN: MTC SU: PDT

DB -- MN001 -- 2930 06/17/93 09:08 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1993
Words:296
Previous Article:K-SWISS ANNOUNCES CLOSING OF PUBLIC OFFERING OF CLASS A COMMON STOCK
Next Article:HICKEY NAMED TO AEQUITRON BOARD OF DIRECTORS
Topics:


Related Articles
THE ORPHAN MEDICAL DIVISION OF CHRONIMED ANNOUNCES EXCLUSIVE LICENSE TO DEVELOP L-CYCLOSERINE FOR GAUCHER'S DISEASE
CHRONIMED ANNOUNCES EXCLUSIVE SUBLICENSE TO DEVELOP 4-METHYL PYRAZOL
THE ORPHAN MEDICAL DIVISION OF CHRONIMED INC. ANNOUNCES AN EXCLUSIVE WORLDWIDE LICENSE WITH M.D. ANDERSON CANCER CENTER TO DEVELOP I.V. BUSULFAN
CHRONIMED ANNOUNCED PAYMENT DATE FOR ORPHAN MEDICAL, INC. DIVIDEND
CHRONIMED AND THE PRUDENTIAL TO CO-DEVELOP COST-SAVINGS SPECIALTY PHARMACY PROGRAM
CHRONIMED ANNOUNCES SELECTION OF NORMAN COCKE AS NEW CHIEF FINANCIAL OFFICER
Orphan Medical and Chronimed Terminate Distribution Agreement; Chronimed to Receive Compensation Valued at $2.5 Million
ChiRex Obtains Exclusive License For Amino Acid Technology From Harvard University.
Cambridge NeuroScience Obtains Exclusive Rights to Neuregulin-2 Growth Factor From Harvard University.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters